Elsevier established a free COVID-19 resource center in January 2020, offering English and Mandarin information on the virus. The center grants permission to share research freely in PubMed Central and other repositories for research use. A study on 400 hospitalized COVID-19 patients found that D-dimer levels at admission predicted bleeding, thrombosis, critical illness, and death. Thrombotic complications occurred in 9.5% of patients, with 4.8% experiencing bleeding. Critically ill patients had higher rates of both. Elevated D-dimer, platelet count, CRP, and ESR were predictive of thrombosis and bleeding. Inflammatory markers like CRP, ESR, ferritin, and procalcitonin were higher in patients with thrombotic complications. DIC, thrombocytopenia, and low fibrinogen were rare but associated with bleeding. The study suggests that intensified anticoagulation may be beneficial but requires further research. The study highlights the importance of coagulation and inflammatory markers in predicting outcomes in COVID-19 patients. The findings indicate that D-dimer levels at admission are strongly associated with critical illness and death. The study also notes that thrombosis and bleeding are common in critically ill patients, with a higher risk of major bleeding. The study emphasizes the need for randomized trials to determine the optimal anticoagulation strategy for COVID-19 patients. The study found that D-dimer levels were disproportionately elevated compared to other coagulation parameters, suggesting a distinct coagulopathy in COVID-19. The study also notes that the observed bleeding rates suggest caution in intensifying anticoagulation in critically ill patients. The study concludes that COVID-19 is associated with similar rates of thrombosis and bleeding as seen in other critically ill patients. The study highlights the importance of coagulation and inflammatory markers in predicting outcomes in COVID-19 patients. The study also notes that the observed bleeding rates suggest caution in intensifying anticoagulation in critically ill patients. The study concludes that further research is needed to determine the optimal anticoagulation strategy for COVID-19 patients.Elsevier established a free COVID-19 resource center in January 2020, offering English and Mandarin information on the virus. The center grants permission to share research freely in PubMed Central and other repositories for research use. A study on 400 hospitalized COVID-19 patients found that D-dimer levels at admission predicted bleeding, thrombosis, critical illness, and death. Thrombotic complications occurred in 9.5% of patients, with 4.8% experiencing bleeding. Critically ill patients had higher rates of both. Elevated D-dimer, platelet count, CRP, and ESR were predictive of thrombosis and bleeding. Inflammatory markers like CRP, ESR, ferritin, and procalcitonin were higher in patients with thrombotic complications. DIC, thrombocytopenia, and low fibrinogen were rare but associated with bleeding. The study suggests that intensified anticoagulation may be beneficial but requires further research. The study highlights the importance of coagulation and inflammatory markers in predicting outcomes in COVID-19 patients. The findings indicate that D-dimer levels at admission are strongly associated with critical illness and death. The study also notes that thrombosis and bleeding are common in critically ill patients, with a higher risk of major bleeding. The study emphasizes the need for randomized trials to determine the optimal anticoagulation strategy for COVID-19 patients. The study found that D-dimer levels were disproportionately elevated compared to other coagulation parameters, suggesting a distinct coagulopathy in COVID-19. The study also notes that the observed bleeding rates suggest caution in intensifying anticoagulation in critically ill patients. The study concludes that COVID-19 is associated with similar rates of thrombosis and bleeding as seen in other critically ill patients. The study highlights the importance of coagulation and inflammatory markers in predicting outcomes in COVID-19 patients. The study also notes that the observed bleeding rates suggest caution in intensifying anticoagulation in critically ill patients. The study concludes that further research is needed to determine the optimal anticoagulation strategy for COVID-19 patients.